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Introduction
Osteoporosis is a systemic skeletal disease resulting in reduced bone mineral density (BMD), deteriorated bone microarchitecture and reduced bone strength, which increases the susceptibility to low energy or fragility fractures [1, 2] . The osteoporosis diagnosis is defined by dual X-ray absorptiometry (DXA)-derived BMD of ≤2.5 standard deviations (SD) below the mean of a young, healthy reference population [3] . The age-dependent decrease in BMD is a strong driver of the increase in fracture risk seen with advanced age [4] [5] [6] (Fig. 1 ).
Every SD decrease in BMD of the hip increases the risk of hip fracture by 2-3 times [7] (Fig. 1) . Osteoporotic fractures are very common, and approximately 50% of women and 20% of men, after the age of 50 years, will sustain a fragility fracture during their remaining lifetime [8] . Fractures of the spine and hip are particularly serious and associated with reduced physical function, worsening quality of life and increased mortality [9] [10] [11] [12] [13] . The total annual cost for osteoporotic fractures has been estimated to $20 billion in the United States and [1] $30 billion in the European Union [1] .
In the late 1980s, the few options available for physicians treating osteoporosis included hormone replacement therapy, calcium and vitamin D and calcitonin. Since then, the pathogenesis of osteoporosis has been largely unravelled, and several effective and safe therapeutics to treat osteoporosis and prevent fractures have been developed and thoroughly tested in large randomized and placebo-controlled trials [14] . Few fields in medicine have experienced such a rapid progress. Furthermore, case finding strategies, using for example, the validated Fracture Risk Assessment Tool (FRAX), which incorporate several clinical risk factors and BMD, have been introduced and is now widely used [15] . Despite this remarkable progress, evaluation and treatment rates have fallen in women with recent fragility fracture in the United States, likely as a result of fear of rare side-effects with bisphosphonates. For example, between 2004 and 2013, the proportion of women who received bisphosphonate treatment after a hip fracture decreased from 15% to 3% [16] . This review will describe the currently available osteoporosis treatments and their use, discuss the evidence for screening, using the fracture risk calculator FRAX and Fracture Liaison Services (FLS), effects of sequential treatment, starting with bone-building drugs, followed by an antiresorptive, and review novel osteoporosis treatment strategies for fracture prevention.
Currently used osteoporosis medication

Bisphosphonates
The most widely used osteoporosis medications are the antiresorptive agents, which reduce the rate of bone remodelling by inhibiting osteoclast activity and thereby bone resorption. The antiresorptive effect exerted by the bisphosphonates depends on their hydroxyapatite affinity, their distribution and duration in bone and their ability to inhibit the enzyme farnesyl pyrophosphate synthase (FPPS) in osteoclasts [17] . The bisphosphonates are the most commonly used antiresorptive agents and are usually the first in line choice when initiating treatment [18, 19] . They include the once weekly orally administered alendronate and risedronate, the once monthly orally administered ibandronate and the once yearly intravenously administered zoledronic acid [20] . As shown in large randomized, placebo-controlled trials in women with postmenopausal osteoporosis, the bisphosphonates increase BMD over 3 years at the spine and hip by approximately 4-9% and 2-6%, respectively [21] [22] [23] [24] [25] [26] . In postmenopausal women with osteoporosis, alendronate, zoledronic acid and risedronate reduced the risk of vertebral (by 40-70%), nonvertebral (by 25-40%) and hip fractures (by 40-53%) compared to placebo over 3 years of treatment [23, 26, 27] . For radiographic vertebral fractures, a reduced risk with treatment can be seen already at 12 months for risedronate and zoledronic acid [22, 24] . For clinical vertebral fractures, a pooled-post hoc analysis of alendronate trials revealed a reduced risk as soon as 12 months of treatment [26] .
Denosumab
The most potent antiresorptive agent is denosumab [28] , a monoclonal antibody to the receptor activator of nuclear factor-kB ligand (RANKL). RANKL is a key regulator of bone resorption by its effect on osteoclast development, function and survival [29] [30] [31] . Amongst the antiresorptives, denosumab is the most potent, as reflected by its ability to reduce the bone resorption marker C-telopeptide of type I collagen (CTX) by about 90% shortly after administration. In a large randomized placebo-controlled trial (FREEDOM) of 7868 postmenopausal women with osteoporosis, biannual 60 mg subcutaneous denosumab (Prolia â ) was able to increase BMD by 9.2% in the spine and 6.0% in the hip, compared to placebo [32] . Over the 36-month study, denosumab reduced the risk of new radiographic vertebral fracture by 4.8% (2.3% vs. 7.2%, P < 0.001) corresponding to a 68% relative risk reduction. The relative risk of hip and nonvertebral fracture was reduced by 40% and 20%, respectively. The incidence of adverse and serious adverse events was balanced between the denosumab and placebo groups, with no increased risk of cancer, cardiovascular disease, delayed fracture healing or hypocalcemia with denosumab treatment [32] . In contrast to the bisphosphonates, for which BMD increases level off and plateaus after 4-5 years [33, 34] , long-term treatment with denosumab leads to continuously increasing BMD for up to 10-years of Hip bone density (T-score) Relative risk of fracture 10 Fig. 1 The relationship between hip bone mineral density T-score and fracture risk. Adapted from: Marshall et al. [7] .
Treating osteoporosis to prevent fractures / M. Lorentzon treatment [35] . In 2343 women from the FREE-DOM trial, 10 years of continuous denosumab increased BMD in the spine and total hip by 21.7% and 9.2%, respectively. The rate of vertebral and nonvertebral fractures and the incidence of adverse events remained low throughout the study duration.
There were two adjudicated AFF during the study, corresponding to an incidence rate of 0.8/10 000 participant-years. Based on 13 adjudicated cases of ONJ, the incidence was 5.2/ 10 000 participant-years of denosumab exposure. Thus, available evidence suggests that long-term treatment with denosumab induces substantial increases in BMD with maintained anti-fracture efficacy and is not associated with any substantial safety concerns. In postmenopausal women with osteoporosis and with previous long term (median 6 years) per oral bisphosphonate use, switching to denosumab, rather than to zoledronic acid, induced greater gains in spine (2.1%) and total hip (1.4%) in BMD over 12 months treatments [36] , indicating that switching to denosumab should be preferred if the BMD response to oral bisphosphonates is insufficient. Because denosumab is not incorporated into the bone, its effect on the skeleton is fully reversible, resulting in rapid loss in BMD after treatment cessation [37] . A rebound phenomenon of rapidly increased bone turnover, with serum CTX reaching a median of 60% above baseline values, has been observed after denosumab discontinuation [37] . Published case reports revealed that some patients discontinuing with denosumab experienced severe vertebral fractures [38] . The risk of vertebral and other fractures was therefore investigated in 1001 women discontinuing denosumab (≥2 doses) treatment in the FREEDOM and Extension studies [39] . The rate of vertebral fracture increased from 1.2 per 100 participantyears to 7.1, which was similar to the rate observed in women discontinuing placebo. However, the proportion of women with multiple vertebral fractures was greater amongst those who discontinued denosumab (60.7%) than placebo (38.7%; P < 0.049), which corresponded to a 3.4% and 2.2% absolute risk of multiple vertebral fractures, respectively. The risk of off-treatment nonvertebral fractures was not elevated in the denosumab group compared to the placebo group. A prior vertebral fracture increased the risk of sustaining multiple vertebral fracture in the off-treatment period. This study was limited by the short off-treatment follow-up time (median of 0.5 years). In an observational study, patients who discontinued with denosumab after 8 years of treatment, those who were switched to another antiresorptive treatment had smaller declines in BMD than those who were not [40] . Therefore, current recommendations state that patients at high risk should either continue with denosumab or switch to another antiresorptive therapy, in order to avoid the rebound increased bone turnover and the accompanying increased risk in multiple vertebral fractures [41] .
Teriparatide and the reappraisal of bone anabolic drugs
Continuously elevated levels of parathyroid hormone, as seen in primary hyperparathyroidism, cause bone loss, especially at cortical bone sites [42] , and increased fracture risk [43] , whilst intermittent administration of the recombinant parathyroid hormone fragment (PTH 1-34 or teriparatide) via subcutaneous injection, leads to a bone formation and increased bone mass [44, 45] . Teriparatide acts on the PTH receptor 1 and induces a substantial increase in bone formation markers and to a lesser a degree, an increase in bone resorption markers, with the net difference in formation and resorption representing the anabolic effect on bone [44] . In the pivotal Fracture Prevention Trial, postmenopausal women with a vertebral fracture were assigned to daily treatment with either 20 or 40 lg teriparatide administered subcutaneously or placebo for 21 months. BMD of the spine increased by 9%, and the risk of vertebral and nonvertebral fractures was reduced by 65% and 53%, respectively, with the 20 lg daily dose compared to placebo. Teriparatide is superior to alendronate in increasing BMD at the spine and hip [46, 47] , but head-to-head trials investigating the effect of teriparatide and a bisphosphonate on fracture risk have until recently been lacking [48] . In the recently published VERO trial, the effect of teriparatide versus risedronate on incident radiographic vertebral fracture in women with severe osteoporosis was investigated [49] . After 24 months, incident vertebral fractures occurred in 5.4% of women in the teriparatide group and in 12.0% in the risedronate group, corresponding to a relative risk reduction of 56% with teriparatide treatment. The incidence of clinical fractures was also substantially lower with teriparatide (4.8% vs. 9.8% or 52% RRR; Fig. 2 and Table 1 ).
Due to the high cost of teriparatide, many guidelines recommend its use be restricted to patients with very high risk and existing vertebral fractures [19, 50] . In 2017, the European Medicines Agency authorized two teriparatide biosimilars (Movymia and Terrosa), which are expected to be provided to the market at a lower cost than Forteo. The expected falling costs for teriparatide and the recently reported superiority in fracture prevention over antiresorptive therapy, will likely lead to a renaissance with more widespread use of teriparatide to prevent fractures in the future.
Abaloparatide
The novel synthetic parathyroid hormone-related protein analogue abaloparatide was recently approved for the treatment of postmenopausal osteoporosis in the United States. In a 24-week dose-finding phase 2 study in 222 healthy postmenopausal women with osteoporosis, participants were assigned to daily subcutaneous abaloparatide in doses of 20, 40, 80 lg or placebo. Abaloparatide was found to increase BMD at the total hip, femoral neck and lumbar spine, in a dose-dependent manner, and more than placebo at 24 weeks. The 40 and 80 lg abaloparatide doses caused greater increases in total hip BMD than those seen with teriparatide [51] . The increase in bone turnover markers was greater with teriparatide than in any of the abaloparatide dosing groups. Abaloparatide-related adverse events were similar across groups and were mostly moderate or mild. This study was followed by the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, a phase 3, double-blind, randomized, international multicenter trial. Postmenopausal women with osteoporosis at the lumbar spine or femoral neck (T-score ≤2.5 SD but >À5 SD) and radiology confirmed lumbar or thoracic vertebral fracture (≥2 mild or ≥1 moderate) or women with a history of nonvertebral low trauma fracture during the last 5 years were eligible for the study. Also, postmenopausal women ≥65 years fulfilling the fracture and T-score criteria (≤2.5 SD and >À5 SD) or those with severe osteoporosis without fracture (≤3.0 SD but >À5 SD) were enrolled. The primary outcome was incidence of new morphometric vertebral fracture. Of the 2463 enrolled women (mean age 69 years), 1901 (77.2%) completed the 18-month trial [52] . Participating women were randomized to either daily s.c. 80 lg abaloparatide or placebo or open label daily subcutaneous 20 lg teriparatide. Abaloparatide treatment reduced the absolute risk of new morphometric vertebral fracture by 3.6% (0.6% vs. 4.2%) compared to placebo, corresponding to a relative risk reduction of 86% (P < 0.001). The incidence of nonvertebral fracture was 2% lower (2.7% vs. 4.7%) in the abaloparatide arm than in the placebo arm (43% relative risk reduction, P = 0.049). BMD at the lumbar spine, femoral neck and total hip increased rapidly with abaloparatide treatment with increments significantly greater than for placebo at all time-points (6, 12 and 18 months). Compared to placebo, abaloparatide treatment increased BMD by 4.25% for the total hip, 4.01% for the femoral neck and 10.4% for the lumbar spine at 18 months. The incidence of 4-h post dose hypercalcemia was significantly lower (P = 0.01) with abaloparatide (3.4%) than with teriparatide treatment (6.4%).
There was no apparent imbalance in serious adverse events between groups: 11% for placebo, 9.7% for abaloparatide and 10.0% for teriparatide. However, there were more adverse events leading to discontinuation in women with abaloparatide (9.9%) than placebo (6.1%) or teriparatide (6.8%).
The effect of anabolic treatment on bone is reversible and leads to declining BMD if treatment is discontinued. Sequential treatment starting with teriparatide and followed by alendronate has demonstrated even further increases in BMD caused by an antiresorptive [53, 54] . In the ACTIVExtend study, the effect of 24 months of alendronate was investigated in women who completed the ACTIVE trial. In total, 1139 (92%) of the 1243 women who completed the abaloparatide or placebo arm of the ACTIVE trial were included in ACTIVExtend trial. During the 43-month study, 0.9% of women in the abaloparatide to alendronate group had a morphometric vertebral fracture, compared to 5.6% of women in the placebo to alendronate group [55] . The relative risk of nonvertebral, clinical and major osteoporotic fractures was reduced by 39%, 34% and 50% (P < 0.05 for all) in the abaloparatide to alendronate compared to the placebo to alendronate group. Thus, the ACTIVExtend trial demonstrated that sequential treatment with the anabolic abaloparatide followed by alendronate results in superior fracture prevention compared to alendronate alone.
The differences in BMD between placebo and abaloparatide at 18 months in ACTIVE were maintained during the 24 months of alendronate treatment in ACTIVExtend [55] . Abaloparatide (Tymlos â ) is available for treatment of postmenopausal osteoporosis at high risk of fracture in the United States [56] , but not in the European Union (EU), as a result of the European Medicines Agency's (EMA) refusal of marketing approval of abaloparatide in the EU. According to EMA, the refusal was due to poor compliance to good clinical practice at two study sites, inability of the study documentation to convincingly demonstrate efficacy for nonvertebral fracture prevention and due to an observed increase in palpitations and heart rate with abaloparatide treatment [57] .
The treatment gap and aspects of treatment duration
Despite availability of well-proven, effective and inexpensive bisphosphonates, only a very small and over time declining proportion of postmenopausal women with high fracture risk are evaluated for osteoporosis and receive these compounds in order to prevent fractures [16, [58] [59] [60] . Fear or rare side-effects such as ONJ and atypical femur fracture (AFF) triggered by warnings issued by the FDA, accompanied by media reports, describing the increased risk of these very rare, but serious adverse events, have likely contributed to this negative development [16, 61] . Over 90% of ONJ cases occur in oncology patients, and the risk in osteoporosis patients is much lower and has been estimated to 1-90 per 100 000 patient-years exposed to bisphosphonates [62] . Risk factors for ONJ in osteoporosis patients include with dentoalveolar surgery, periodontal disease and concomitant per oral glucocorticoid use [63] .
Atypical femur fractures account for about 4-5 out of every 1000 femur fractures [64] and can occur also in patients without osteoporosis medication, but the risk of AFF increases with bisphosphonate use and with duration of bisphosphonate use [20] .
In a large population in southern California, the incidence of AFF in patients with less than 2 years of bisphosphonate exposure was estimated to 1.78/100 000 patient-years and rose with duration of exposure, to 113/100 000 patient-years in patients with 8-10 years of exposure [65] . Based on calculations from performed meta-analysis and reviews, 5 years of bisphosphonate use will cause less than 1 AFF per 100 other prevented fractures [20, 66, 67] . Since the absolute risk of AFF is much lower than for hip or other fracture, even long-term treatment with bisphosphonates has been associated with an acceptable benefit-to-risk ratio [68] . Two randomized and placebo-controlled trials investigated effects on BMD and anti-fracture efficacy with prolonged bisphosphonates in postmenopausal women. Continued treatment for up to 10 years vs. 5 for alendronate and for 6 years vs. 3 for zoledronic acid resulted maintained BMD levels and reduced the risk of vertebral but not of other fractures [33, 34] . Based on these findings and acceptable benefit-to-risk ratio with long-term treatment, the American Society for Bone and Mineral Research Task Force recommended that treated patients should be evaluated after 3 and 5 years treatment with zoledronic acid and alendronate, respectively. According to these recommendations, continued treatment, with periodical evaluation, should be considered in patients with remaining high risk at evaluation (low hip BMD Tscore or high fracture risk score) [69] .
Using sclerostin inhibitors to prevent fractures -a dual mode of action on bone
By investigating the genetic basis for skeletal abnormalities found in patients with van Buchems disease and Sclerostosis, mutations in the SOST gene, coding for the sclerostin protein mainly expressed in osteocytes, were identified [70] [71] [72] .
Patients heterozygous for mutations in the SOST gene have a normal life-span, increased bone formation and bone mass and seldom sustain fractures [73, 74] . Homozygous mutations cause a more severe phenotype, which include skeletal overgrowth and cranial nerve compression [75] . By binding to the extracellular domain of lipoprotein (LRP) 4, 5 and 6, sclerostin prevents binding of Wnt ligands to the LRPs and to Frizzled, which result in inhibition of Wnt signalling and in bone, leading to effective inhibition of osteoblastic activity and bone formation [76, 77] . Figure 3 describes the mechanisms of action for sclerostin antibody inhibition.
In a phase I, randomized and placebo-controlled trial, the sclerostin monoclonal antibody AMG785 (later renamed to romosozumab) was found to increase bone formation markers and decrease bone resorption markers in a dose-dependent manner. This dual mode of action is different from the anabolic compound teriparatide, which increases both bone formation and resorption (Fig. 4) [78] .
Increments of over 5% in spine BMD was seen with a single dose of the antibody [79] . In a phase II, randomized trial, in 419 postmenopausal women with low BMD (a T-score of À2 or less in the lumbar spine, total hip or femoral neck), the 210 mg monthly dose of romosozumab increased BMD in the lumbar spine by 11.3% and in total hip by 4.1% in 12 months [80] . These increments were larger than those seen in the alendronate and teriparatide groups. The effect of monthly romosozumab on incident vertebral fracture was investigated in the phase III trial FRAME trial [81] . In total, 7180 postmenopausal women with a BMD T-score of À2.5 to À3.5 at the total hip or femoral neck were randomized to either 210 mg subcutaneous romosozumab or placebo for 12 months, followed by denosumab for an additional 12 months. The incidence of new vertebral fracture was lower in the romosozumab than in the placebo group at 12 (0.5% vs. 1.8%; relative risk reduction 73%, P < 0.001) and at 24 months (0.6% vs. 2.5%; relative risk reduction 75%, P < 0.001). At 12 months, romosozumab treatment was also associated with a 36% relative risk reduction in clinical fracture (1.6% vs. 2.5%, P = 0.008) compared to placebo. However, the romosozumab associated reduction in nonvertebral fractures, which account for >85% of all clinical fractures, did not reach statistical significance (1.6% vs. 2.1%, P = 0.10) at 12 or 24 months (2.7% vs. 3.6%, P = 0.06). Post hoc analysis revealed that the nonvertebral fracture prevention efficacy of romosozumab was dependent on baseline fracture risk and was more pronounced (1.5% vs. 2.4% for placebo, corresponding to a relative risk reduction of 36%, P = 0.029) and statistically significant in the subgroup of 5089 women with high fracture risk, defined as a 10-year probability of ≥20% for major osteoporotic fracture or as ≥3% in hip fracture, according to FRAX [82] .
The effectiveness of a sequential treatment regimen, starting with romosozumab and transitioning to alendronate vs. treatment with alendronate alone, in reducing the risk of fracture was investigated in the active-controlled fracture study in postmenopausal women with osteoporosis at high risk (ARCH) trial [83] . ARCH was an international, multicenter, double-blind, randomized trial, in which 4093 postmenopausal women, 55-90 years old, with osteoporosis and a fragility fracture, were randomized to either 210 mg of monthly romosozumab or alendronate for 12 months, followed by open label alendronate in both treatment groups. The prevalence of vertebral fracture was high (96%) and BMD low (approximately À2.9 in T-score in the lumbar spine and femoral neck) which contributed to the high baseline FRAX score (20% for major osteoporotic fracture) in the participating women. The primary end-points were the cumulative incidence of vertebral fracture at 24 months and cumulative incidence of clinical fracture at the time of the primary analysis, which was event driven (≥330 women with clinical fracture) and occurred after 2.7 years (2.2-3.3, median and interquartile range). Women who received romosozumab had 48% lower risk of vertebral fractures (6.2% vs. 11.9%, P < 0.001) than women who received alendronate at 24 months ( Fig. 5 and Table 1 ).
The risk of clinical, nonvertebral and hip fractures were reduced by 27% (9.7% vs. 13%, P < 0.001), 19% (8.7% vs. 10.6%, P < 0.04) and 38% (2.0% vs. 3.2%, P = 0.02) in romosozumab treated women, respectively. There were no cases ONJ or AFF during the 12-month double-blind period, but during the alendronate open label period there was one case of ONJ in each group. In the latter period, six events of AFF occurred, 2 (<0.1%) in the romosozumab to alendronate group and 4 (0.2%) in the alendronate to alendronate group. Overall, adverse events and serious adverse events were similar between treatment arms. However, during the first 12 months, positively adjudicated serious cardiovascular events were observed more frequently in the romosozumab than in the alendronate group (2.5% vs. 1.9%). Although there was no evidence of an imbalance in cardiovascular adverse events in the FRAME trial, which in contrast to ARCH was a placebo-controlled trial, the concern for cardiovascular safety has complicated the evaluation of romosozumab's safety. Applications for registration have been submitted and are being evaluated, at the time of this article's preparation, to the European medicinal agency in the EU and the Food and Drug Administration in the USA.
Optimizing use of osteoporosis medication with sequential treatment
Single use of any of the current osteoporosis medication has limitations. Antiresorptive and anabolic treatment alone can only reduce risk of nonvertebral fractures by 20-40% and by 43-53%, respectively [23, 26, 27, 32, 44, 52] . Thus, most treated patients will suffer from these fractures despite having treatment. Bisphosphonates are commonly restricted to a 3-to 5-year treatment duration, due to fear of rare side-effects such as ONJ and AFF [84, 85] , and anabolics have a 2-year regulatory imposed limit for their use. Thus, a short-term treatment with a compound from either drug class will not be able to prevent the majority of fractures over the course of perhaps 20-30 years in an osteoporosis patient's life.
The anabolic effect of intermittent teriparatide or PTH on the skeleton results in substantial increases in BMD especially in the spine but also in the hip. Once teriparatide is discontinued, a gradual loss in BMD starts [86] . Some residual effect in fracture reduction is maintained after treatment cessation [87] , but this effect will likely fade and disappear with time. Several strategies have been proposed to prevent loss of BMD gains obtained by anabolic treatment. One year of alendronate treatment after 1 year of intermittent PTH was able to induce further increases in BMD of the spine and hip in postmenopausal [53, 88] . Two years of teriparatide treatment followed by 2 years of denosumab biannually, a combination of the two, or a reverse sequence of medications, was tested in postmenopausal women with osteoporosis in the DATA-switch study [89] . Spine and total hip BMD increased by over 18% and 6%, respectively, in the group receiving denosumab after teriparatide, with increments of over 9% and nearly 5% at these skeletal sites, seen over the 24-months with denosumab treatment.
In contrast, the treatment sequence starting with denosumab and ending with teriparatide resulted in transient or continuous bone loss, as a result of increased bone turnover with teriparatide. Although the effects on spine BMD of teriparatide appear to be somewhat blunted in patients previously treated with potent bisphosphonates [90, 91] , the largest treatment sequence-dependent effects are seen for hip BMD [54] . A transient bone loss or absence of BMD gains at the total hip has been observed for up to 12 months in patients transitioning from risedronate or alendronate to teriparatide [54, 91, 92] . Thus, it is possible that the strength of the hip declines during this period, resulting in increased susceptibility to hip fracture. In many countries, anabolic treatment is used as a rescue treatment, recommended if BMD falls or if the patient suffers from fractures whilst on bisphosphonate treatment. In fact, a large database study from the United States showed that the majority of patients starting teriparatide were previously treated with antiresorptives [93] . Thus, with current practice, optimal benefit of anabolic treatment is not attained.
In the ACTIVExtend study, BMD of the spine and total hip continued to increase during the 24-month alendronate treatment period, following the initial 18 months of abaloparatide [55] . Data from large randomized and placebo-controlled trials have also revealed that the dramatic increases in BMD seen with romosozumab treatment can be maintained or increased if romosozumab is followed by denosumab [81] or alendronate [83] . With sequential treatment, a larger proportion of patients will move away from low BMD T-scores and therefore benefit from long-term reductions in fracture risk.
Data from the ACTIVExtend, FRAME and ARCH studies demonstrate that sequential treatment, starting with a bone-building drug, followed by an antiresorptive agent, results in maintained reductions in fracture risk. Altogether, these findings clearly demonstrate that optimal use of current osteoporosis medication is sequential treatment, starting with a bone building, followed by an antiresorptive drug. This treatment strategy is the most likely to provide long-term benefits in fracture risk reduction and should be considered for patients in whom 3-5 years of bisphosphonates would not be likely to reverse an increased fracture risk. A schematic presentation of the effect of a bone-building agent and/or sequential treatment on BMD and vertebral fracture risk is shown in Fig. 6 . Case finding and screening with FRAX Given the effectiveness, safety and underutilization of osteoporosis drugs in patients at high risk, steps should be taken to minimize the treatment gap.
Older patients with a recent fragility fracture have a dramatically increased risk -also known as imminent fracture risk -of a subsequent fracture, exceeding five times, within the first 2 years following the index fracture [94, 95] . This phenomenon has put additional focus on the need of organized health care pathways or FLS, designed to identify, evaluate and treat older patients with fragility fractures. There is now overwhelming evidence that FLS lead to a substantial increase in the proportion of patients who receive osteoporosis treatment after a fragility fracture [96, 97] . The most comprehensive FLS, using a coordinatorbased approach for the identification, evaluation (with DXA and screening of clinical risk factors) and initiation of osteoporosis medication, results in a more than doubled proportion, reaching nearly half, of women receiving treatment after a fragility fracture [98] . Reports from Scotland and in the United States have demonstrated that FLS were cost-effective compared to usual care [99, 100] . In a large randomized trial of 2127 men and women with a recent hip fracture, 5 mg zoledronic acid, once yearly for 3 years, reduced the risk of clinical fracture by 35% (8.6% in the zoledronic acid group and 13.9% in the placebo group, P = 0.001) [101] . Although studies investigating the effect of bonebuilding drugs in an FLS setting are lacking, it is conceivable that these drugs could have an even larger impact than an antiresorptive agent on the imminent fracture risk.
Even though the case for secondary prevention of osteoporotic fractures is particularly strong, it could be argued that an intervention should not have to be postponed until the first fracture occurs. A large randomized controlled trial (n = 12 483) investigating the effect of screening in the community to prevent fracture was recently completed [102] . Women were recruited from 100 general practitioners' practices in the United Kingdom, were 70-85 years old and were randomized to either a screening programme using the FRAX or to usual care. Women in the screening group were recommended treatment if the 10-year risk of hip fracture was elevated. After the first year in the study, the intervention resulted in more women receiving treatment in the screening group than in the control group (15% vs. 4%). 
Primary fracture prevention by targeting osteopenic women
Based on data from large studies such as the National Osteoporosis Risk Assessment study [103] , with over 150 000 women, and the Rotterdam study [104] with more than 14 000 women, it can be concluded that the vast majority of fractures occur in osteopenic women, that is, women with a BMD T-score of between À1 and À2.5 SD. Thus, in order to be successful in preventing the majority of fractures, women with osteopenia should also be targeted. One infusion with zoledronic acid has been shown to reduce bone turnover, increase BMD and reduce the risk of clinical fracture for up to 3 years [105, 106] . In a recent 6-year study of 2000 osteopenic women, 65 years and older, Reid et al. reported that iv. zoledronic once every 18 months, which was less frequently administered than in previous trials [24, 101] , was able to increase BMD and reduce the risk of fragility fractures [107] . In total, 122 women with zoledronate treatment and 190 with placebo experienced a fracture during the study, corresponding to a relative risk reduction of 37% (95% CI: 21-50% Bone turnover markers were substantially lower (procollagen type 1 N-propeptide 37% lower and the carboxy-terminal collagen crosslinks 50% lower, P < 0.001) at 6 years than at baseline in the zoledronic acid whilst no differences were seen in the placebo-treated women, demonstrating a sustained antiresorptive effect of zoledronic treatment.
In the light of these results, it could be argued that primary fracture prevention by screening of women 65 years and older with DXA should be recommended, so that those with osteopenia could be offered zoledronic acid every 18 months.
Conclusions
Currently available osteoporosis medications are effective and safe and should be more appropriately used, so that patients at high risk should to a much higher extent be evaluated and treated than what is current practice. FLS and communitybased screening using FRAX constitute effective approaches. For patients at high risk and more severe osteoporosis, sequential treatment, starting with a more effective bone-building drug (as illustrated in Fig. 6 in Table 1 ), followed by an antiresorptive agent, will likely provide better long-term fracture prevention and should be the golden standard of future osteoporosis treatment. Instituting these measures will likely have a profound effect on reducing fracture rates in the future.
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